ROCKAWAY, N.J. , Sept. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger , will present at the H.C. Wainwright 25th Annual Global Investment Conference . H.C.
ROCKAWAY, N.J. , Aug. 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal
Record second quarter 2023 net sales of $3.6 million , an increase of approximately 65% over second quarter 2022 Company to host a conference call and webcast today, August 9, 2023 at 4:30 PM EDT ROCKAWAY, N.J. , Aug. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc.
ROCKAWAY, N.J. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of the market on Wednesday, August
ROCKAWAY, N.J. , July 31, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to certain institutional and accredited investors an aggregate
ROCKAWAY, N.J. , July 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed manuscript, Effect of Transcutaneous Cervical Vagus Nerve Stimulation on Declarative and Working
ROCKAWAY, N.J. , July 18, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office (USPTO) has issued a patent related to non-invasive nerve stimulation with mobile
ROCKAWAY, N.J. , July 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Reletex TM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea
Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022 ROCKAWAY, N.J. , July 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today
ROCKAWAY, N.J. , July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its gammaCore non-invasive vagus nerve stimulation (“nVNS”) has been selected to be a part of studies on effects of cannabinoids